A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
ConditionAlzheimer's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorEisai Co., Ltd.
About this trial
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Eligibility criteria
Qualifiers
All participants who are treated with lecanemab in routine clinical practice
Disqualifiers
None
Trial design
Treatments tested in this trial
- No Intervention
Treatment groups
5,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov